On the other hand, a high expression of S100A2 was associated with a poorer prognosis in patients with nonsmall-cell lung cancer, hepatocellular carcinoma, ovarian cancer, endometrial carcinoma, pancreatic cancer, prostate cancer, oral squamous cell carcinoma, colorectal cancer, cholangiocarcinoma. Here, S100A2 is linked to prostate cancer.